

Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Dec-2016  
Document Type: USP Monographs  
DocId: GUID-FE7CCE68-66B4-409C-9DD1-C04830A444DF\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M75105\\_01\\_01](https://doi.org/10.31003/USPNF_M75105_01_01)  
DOI Ref: c2hrd

© 2025 USPC  
Do not distribute

## Sertraline Hydrochloride Tablets

### DEFINITION

Sertraline Hydrochloride Tablets contain an amount of sertraline hydrochloride equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ).

### IDENTIFICATION

- **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Mobile phase:** [Methanol](#) and 0.1% (v/v) [phosphoric acid](#) (1:1)

**Standard solution:** 0.05 mg/mL of [USP Sertraline Hydrochloride RS](#) in *Mobile phase*

**Sample stock solution:** 0.5 mg/mL of sertraline free base prepared as follows. Transfer NLT 10 Tablets to a suitable volumetric flask.

Dissolve in 0.1% [phosphoric acid](#) equivalent to 50% of the flask volume. Sonicate for 15 min with intermittent shaking to disperse the Tablets. Add an amount of [methanol](#) equivalent to 40% of the flask volume, and continue to sonicate for an additional 10 min. Cool the solution, and dilute with methanol to volume.

**Sample solution:** Nominally 0.05 mg/mL of sertraline free base in *Mobile phase* from the *Sample stock solution*. Pass a portion of this solution through a nylon filter of 0.45- $\mu$ m or finer pore size, discard the first few mL, and collect the rest of the filtrate.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 210 nm

**Column:** 4.6-mm  $\times$  25-cm; 5- $\mu$ m packing L10

**Column temperature:** 30°

**Flow rate:** 1.5 mL/min

**Injection volume:** 10  $\mu$ L

**Run time:** Twice the retention time of sertraline

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 1.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Sertraline Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of sertraline free base in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of sertraline, 306.23

$M_{r2}$  = molecular weight of sertraline hydrochloride, 342.69**Acceptance criteria:** 90.0%–110.0% of sertraline free base**PERFORMANCE TESTS**• **Dissolution (711)****Test 1****Medium:** Acetate buffer (3.0 g/L of [sodium acetate trihydrate](#) and 1.6 mL/L of [glacial acetic acid](#); adjust with [glacial acetic acid](#) to a pH of 4.5); 900 mL**Apparatus 2:** 75 rpm**Time:** 30 min**Standard stock solution:** 0.56 mg/mL of [USP Sertraline Hydrochloride RS](#) in *Medium*. A small volume of [methanol](#), not exceeding 5% of the final volume, may be used to help solubilize sertraline.**Standard solution****For Tablets labeled to contain 50, 100, 150, or 200 mg:** 0.056 mg/mL of [USP Sertraline Hydrochloride RS](#) in *Medium* from the *Standard stock solution***For Tablets labeled to contain 25 mg:** 0.028 mg/mL of [USP Sertraline Hydrochloride RS](#) in *Medium* from the *Standard stock solution***Sample solution:** Pass a portion of the solution under test through a suitable filter of 0.45- $\mu$ m pore size. Dilute with *Medium*, if necessary.**Mobile phase:** [Acetonitrile](#) and 0.1% (v/v) [phosphoric acid](#) (1:3)**Chromatographic system**(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 210 nm**Column:** 4.6-mm  $\times$  25-cm; 5- $\mu$ m packing L10**Column temperature:** 40°**Flow rate:** 1.5 mL/min**Injection volume****For Tablets labeled to contain 50, 100, 150, or 200 mg:** 10  $\mu$ L**For Tablets labeled to contain 25 mg:** 20  $\mu$ L**System suitability****Sample:** *Standard solution***Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 2.0%**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times D \times V \times 100$$

 $r_U$  = peak response from the *Sample solution* $r_S$  = peak response from the *Standard solution* $C_S$  = concentration of [USP Sertraline Hydrochloride RS](#) in the *Standard solution* (mg/mL) $L$  = label claim (mg/Tablet) $M_{r1}$  = molecular weight of sertraline, 306.23 $M_{r2}$  = molecular weight of sertraline hydrochloride, 342.69 $D$  = dilution factor for the *Sample solution* $V$  = volume of *Medium*, 900 mL**Tolerances:** NLT 80% (Q) of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ) is dissolved.**Test 2:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

**Medium:** pH 4.5 acetate buffer (6.8 g/L of [sodium acetate trihydrate](#) and 32 mL/L of 2 N [acetic acid](#); adjust with 2 N [acetic acid](#) to a pH of 4.5); 900 mL

**Apparatus 2:** 75 rpm

**Time:** 45 min

**Buffer:** 3 mL/L of [glacial acetic acid](#) and 7 mL/L of [triethylamine](#) in water

**Mobile phase:** [Acetonitrile](#), [methanol](#), and [Buffer](#) (10:4:8)

**Standard solution:** (L/800) mg/mL of [USP Sertraline Hydrochloride RS](#) in [Medium](#), where L is the label claim in mg/Tablet

**Sample solution:** Pass a portion of the solution under test through a suitable filter of 0.45- $\mu$ m pore size.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 273 nm

**Column:** 3.9-mm  $\times$  15-cm; 4- $\mu$ m packing L1

**Column temperature:** 30°

**Flow rate:** 1.0 mL/min

**Injection volume:** 20  $\mu$ L

#### System suitability

**Sample:** [Standard solution](#)

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 2.0%

#### Analysis

**Samples:** [Standard solution](#) and [Sample solution](#)

Calculate the percentage of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ) dissolved:

$$\text{Result} = (r_U/r_S) \times (C_S/L) \times (M_{r1}/M_{r2}) \times D \times V \times 100$$

$r_U$  = peak response from the [Sample solution](#)

$r_S$  = peak response from the [Standard solution](#)

$C_S$  = concentration of [USP Sertraline Hydrochloride RS](#) in the [Standard solution](#) (mg/mL)

$L$  = label claim (mg/Tablet)

$M_{r1}$  = molecular weight of sertraline, 306.23

$M_{r2}$  = molecular weight of sertraline hydrochloride, 342.69

$D$  = dilution factor for the [Sample solution](#)

$V$  = volume of [Medium](#), 900 mL

**Tolerances:** NLT 80% (Q) of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ) is dissolved.

**Test 3:** If the product complies with this test, the labeling indicates that it meets USP [Dissolution Test 3](#).

**Medium:** pH 4.5 acetate buffer (6.8 g/L of [sodium acetate trihydrate](#); adjust with 2 N [acetic acid](#) to a pH of 4.5); 900 mL

**Apparatus 2:** 75 rpm

**Time:** 30 min

**Buffer:** Dissolve 0.8 g/L of [ammonium acetate](#) in water and add 10 mL of [triethylamine](#). Adjust with [phosphoric acid](#) to a pH of 5.0  $\pm$  0.05.

**Mobile phase:** [Acetonitrile](#) and [Buffer](#) (35:65)

**Standard stock solution:** 0.6 mg/mL of [USP Sertraline Hydrochloride RS](#) in [Medium](#), prepared as follows. Place an appropriate amount of [USP Sertraline Hydrochloride RS](#) into a suitable volumetric flask and add 70% of the final flask volume of [Medium](#). Sonicate to dissolve and dilute with [Medium](#) to volume. Pass through a suitable filter of 0.45- $\mu$ m pore size.

**Standard solution:** (L/800) mg/mL of [USP Sertraline Hydrochloride RS](#) in [Medium](#) from [Standard stock solution](#), where L is the label claim in mg/Tablet

**Sample solution:** Pass a portion of the solution under test through a suitable filter of 0.45- $\mu$ m pore size.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 220 nm**Column:** 4.6-mm × 15-cm; 5-μm packing L1**Column temperature:** 50°**Flow rate:** 2.0 mL/min**Injection volume:** 20 μL**System suitability****Sample:** Standard solution**Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 1.0%**Analysis****Samples:** Standard solution and Sample solutionCalculate the percentage of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ) dissolved:

$$\text{Result} = (r_u/r_s) \times (C_s/L) \times (M_{r1}/M_{r2}) \times V \times 100$$

 $r_u$  = peak response from the Sample solution $r_s$  = peak response from the Standard solution $C_s$  = concentration of [USP Sertraline Hydrochloride RS](#) in the Standard solution (mg/mL) $L$  = label claim (mg/Tablet) $M_{r1}$  = molecular weight of sertraline, 306.23 $M_{r2}$  = molecular weight of sertraline hydrochloride, 342.69 $V$  = volume of Medium, 900 mL**Tolerances:** NLT 80% (Q) of the labeled amount of sertraline free base ( $C_{17}H_{17}Cl_2N$ ) is dissolved.

- [Uniformity of Dosage Units \(905\)](#): Meet the requirements

**IMPURITIES****• ORGANIC IMPURITIES**

[NOTE—Use freshly prepared samples.]

**Buffer:** 2.72 g/L of [monobasic potassium phosphate](#). Adjust with [triethylamine](#) to a pH of 7.0.**Mobile phase:** [Methanol](#), [acetonitrile](#), and **Buffer** (6:3:11). Adjust with [triethylamine](#) to a pH of 8.0.**System suitability solution:** 5 μg/mL of [USP Sertraline Hydrochloride Racemic Mixture RS](#) and 0.5 mg/mL of [USP Sertraline Hydrochloride RS](#) in Mobile phase**Standard solution:** 2.5 μg/mL of [USP Sertraline Hydrochloride RS](#) in Mobile phase**Sample solution:** [NOTE—Sonicate for about 10 min with shaking to disperse the Tablets.] Prepare a solution of 0.5 mg/mL of sertraline in Mobile phase from NLT 20 powdered Tablets. Pass a portion of this solution through a nylon filter of 0.45-μm or finer pore size, discard the first few mL, and use the filtrate.**Chromatographic system**(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 210 nm**Column:** 4.0-mm × 25-cm; 5-μm packing L45**Flow rate:** 0.7 mL/min**Injection volume:** 20 μL**System suitability****Samples:** System suitability solution and Standard solution

[NOTE—The relative retention times for the 1R,4R-cis-isomer of sertraline and sertraline are 0.9 and 1.0, respectively.]

**Suitability requirements****Resolution:** NLT 1.5 between sertraline and the 1R,4R-cis-isomer of sertraline, System suitability solution**Relative standard deviation:** NMT 5%, Standard solution**Analysis****Samples:** Standard solution and Sample solution

Calculate the percentage of each individual degradation product in the portion of Tablets taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (M_{r1}/M_{r2}) \times 100$$

$r_u$  = peak response of each individual degradation product from the *Sample solution*

$r_s$  = peak response of sertraline from the *Standard solution*

$C_s$  = concentration of [USP Sertraline Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_u$  = nominal concentration of sertraline in the *Sample solution* (mg/mL)

$M_{r1}$  = molecular weight of sertraline, 306.23

$M_{r2}$  = molecular weight of sertraline hydrochloride, 342.69

#### Acceptance criteria

Disregard any peak below 0.1%. Disregard the peak due to the process impurity 1*R*,4*R*-*cis*-isomer of sertraline.

**Individual degradation product:** NMT 0.2%

**Total degradation products:** NMT 2.0%, excluding the 1*R*,4*R*-*cis*-isomer of sertraline

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, and store at controlled room temperature.
- **LABELING:** When more than one *Dissolution* test is given, the labeling states the *Dissolution* test used only if *Test 1* is not used.
- [USP REFERENCE STANDARDS \(11\)](#)

[USP Sertraline Hydrochloride RS](#)

[USP Sertraline Hydrochloride Racemic Mixture RS](#)

(1*RS*,4*RS*)-4-(3,4-Dichlorophenyl)-*N*-methyl-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride.

$C_{17}H_{17}Cl_2N \cdot HCl$  342.69

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
SERTRALINE HYDROCHLORIDE TABLETS	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(1)

**Current DocID: GUID-FE7CCE68-66B4-409C-9DD1-C04830A444DF\_1\_en-US**

**DOI:** [https://doi.org/10.31003/USPNF\\_M75105\\_01\\_01](https://doi.org/10.31003/USPNF_M75105_01_01)

**DOI ref:** [c2hrd](#)